GlaxoSmithKline plc (GSK), a leading global healthcare company headquartered in Great Britain, has been at the forefront of pharmaceutical innovation since its founding in 2000, following the merger of Glaxo Wellcome and SmithKline Beecham. With a strong presence in Europe, North America, and emerging markets, GSK operates primarily in the pharmaceutical, vaccine, and consumer healthcare sectors. The company is renowned for its diverse portfolio, which includes groundbreaking medicines, vaccines, and consumer health products that address a wide range of health needs. GSK's commitment to research and development has led to significant advancements in areas such as respiratory diseases, HIV, and immunology. As a key player in the global healthcare landscape, GSK continues to achieve notable milestones, reinforcing its position as a trusted provider of innovative health solutions.
How does Glaxosmithkline's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Glaxosmithkline's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, GlaxoSmithKline (GSK) reported total carbon emissions of approximately 521,000,000 kg CO2e for Scope 1 and 44,000,000 kg CO2e for Scope 2 globally. In the UK, GSK's combined Scope 1 and 2 emissions were about 92,000,000 kg CO2e. The company has set ambitious climate targets, aiming for net zero emissions across all operations (Scope 1 and 2) by 2030 and a 90% reduction in emissions across all scopes by 2045, using a 2020 baseline. GSK has achieved a 15% reduction in Scope 1 and 2 emissions from 2020 to 2021. Additionally, they are committed to reducing absolute Scope 1 and 2 GHG emissions by 34% by 2025 from a 2017 baseline and Scope 3 emissions by 16% by 2030 from the same base year. Their long-term strategy includes a comprehensive approach to tackle emissions across their entire value chain, with a focus on high-quality offsets for any remaining emissions. GSK's climate initiatives are aligned with the Science Based Targets initiative (SBTi) and include commitments to significant reductions in emissions from purchased goods and services, business travel, and other operational activities. The data reported is sourced directly from GSK plc, ensuring accuracy and consistency in their climate commitments.
Access structured emissions data, company-specific emission factors, and source documents
2010 | 2011 | 2012 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 430,000 | 000,000 | 000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | - | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Glaxosmithkline is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.